PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
59.87
ESG score near Biotechnology median of 61.42. David Dodd would investigate if industry-standard ESG practices adequately address sector-specific risks.
50.00
Environmental score 80-90% of Biotechnology median of 57.52. Martin Whitman would look for hidden carbon liabilities and stranded asset risks.
61.14
Social score near Biotechnology median of 63.32. David Dodd would investigate if industry-standard social practices adequately address stakeholder risks.
68.48
Governance score 1.1-1.2x Biotechnology median of 62.92. Philip Fisher would examine if superior governance practices support long-term value creation.